



Bill Mezzanotte

Executive Vice President, Research and Development
CSL Behring

Bill Mezzanotte is responsible for developing and executing CSL's Research & Development strategy and portfolio, including the identification and development of all R&D platforms, skills and expertise necessary for success.

In April 2017, Bill joined the company as Head of Clinical Development, responsible for clinical science, statistics and clinical operations across CSL Behring's portfolio. Most recently he served as Senior Vice President and Head of Development, where he oversaw regulatory, project management, clinical science & operations, plasma, recombinant protein and gene therapy pharmaceutical development activities worldwide.

Prior to CSL, he was Senior Vice President and Therapeutic Area Head, Respiratory for Boehringer Ingelheim and spent 16 years with AstraZeneca in research and development, assuming roles of increasing leadership and management responsibility across multiple therapeutic areas.

Bill holds an undergraduate degree from Villanova University, obtained his M.D. at the University of Pennsylvania and a Master of Public Health degree from Johns Hopkins University.

Bill is board certified in internal medicine, pulmonary medicine, critical care medicine and sleep medicine.



Andrew Nash
Senior Vice President Research
CSL Limited

Andrew Nash completed his PhD in immunology at The University of Melbourne in 1988 and, after moving to the Centre for Animal Biotechnology in the Faculty of Veterinary Science, developed and led a research group focused on basic and applied aspects of cytokine biology.

In 1996 he joined the ASX listed biotechnology company Zenyth Therapeutics (then Amrad Corporation) as a senior scientist and subsequently held a number of positions including Director of Biologicals Research and Chief Scientific Officer. In July of 2005 he was appointed Chief Executive Officer of Zenyth, a position which he held up until the acquisition of Zenyth by CSL Limited in November 2006. Following the acquisition he was appointed as CSL's SVP, Research and is currently based at the Bio21 Institute where he leads a large global effort focused on the discovery and development of new protein, cell and gene-based medicines to treat serious human disease.



Diana Lanchoney

**Vice President, Clinical Pharmacology & Translational Development
CSL Limited**

Diana was appointed head of Clinical Pharmacology and Translational Development (CPAT) in January 2018. Diana's global responsibility includes Clinical Pharmacology and Translational studies (eg Phase I, Proof of Mechanism), as well as leading product development strategy through Proof of Concept for CSL's early protein therapeutics pipeline. Diana joined CSL in 2014 to lead R&D Project Management, covering CSL's end to end R&D project portfolio, including registration of a large number of CMC expansions at every site of operations.

Prior to joining CSL, Diana spent 14 years at Merck & Co, starting with increasingly senior roles R&D Project and Portfolio Management across all therapeutic areas, with a focus on research and early development (Target to Phase IIb). Later Merck roles included Commercial positions in Medical Affairs and Policy, Strategy and New Product Planning, as well as leading the global Corporate Strategy team for Merck's Chief Strategy Officer.

After undergraduate work at Tufts University, Diana began her career as a credit risk analyst for Chase Manhattan Bank. Inspired by the innovative power of biotech, she soon redirected to life science and spent several years in the lab doing HIV- and HSV-focused basic research. Diana attended medical school and completed Internal Medicine residency at the University of Pennsylvania before achieving her Board Certification.



William Campbell

**Executive Vice President & Chief Commercial Officer
CSL Limited**

Bill was appointed as Executive Vice President & Chief Commercial Officer on July 1, 2017. Bill has responsibility for a variety of global functions including Sales, Marketing, Commercial Development, Medical Affairs, Analytics and Public Policy. Bill is accountable for our global Commercial strategy and leads a team of 1,700 Commercial professionals around the world.

Prior to being appointed to his current role, Bill led CSL Behring's North American Commercial Operations. Bill and his team were responsible for the successful launches of IDELVION, AFSTYLA and HAEGARDA and other new products. Under Bill's leadership, the North American region delivered substantial revenue and volume growth across the portfolio.

Bill has more than 35 years of diverse Pharmaceutical and Biotechnology experience across a range of therapeutic areas, including Oncology, Women's Health, Vaccines, and Plasma Proteins. He has served in a number of progressive senior leadership roles with Wyeth, Abbott, Teva, Cephalon and Centeon, a CSL predecessor company.

In addition to Bill's industry experience, he has previously served on the Board of Directors for the National Kidney Foundation Delaware Valley, the Plasma Protein Therapeutic Association (PPTA) and the Biotechnology Innovation Organization (BIO).



Russell Bassar

Senior Vice President, Research and Development
Seqirus

Russell has been the Senior Vice President of Research and Development since the formation of Seqirus in 2015. He joined CSL in 2001 and for many years led the expanding clinical trial portfolio, including spending two years in the Pennsylvania office leading global Clinical Development. He was Chief Medical Officer of CSL in 2014-15.

Dr Bassar led the clinical and regulatory programs that led to licensure of CSL's influenza vaccine globally (Fluvax in Australia, Afluria in the US, Enzira in Europe), Australian approval of the pre-pandemic H5N1 bird flu vaccine, as well as the 2009 H1N1 swine flu pandemic program.

Since Seqirus was established in August 2015, his team has achieved major regulatory approvals for a novel adjuvanted influenza vaccine (Fluad) and new 4 strain vaccines based on cell culture and egg-based platforms.

Prior to joining CSL, he worked as a medical oncologist at Royal Melbourne and Western Hospitals in Melbourne and was a Fellow at the Ludwig Institute for Cancer Research. He completed his Medical degree and Doctor of Medicine at the University of Melbourne and attained his fellowship with the Royal Australasian College of Physicians.